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Abstract: BACKGROUND The worldwide spread of a novel coronavirus disease (COVID-19) has led to
a near total stop of non-urgent, elective surgeries across all specialties in most affected countries. In the
field of aesthetic surgery, the self-imposed moratorium for all aesthetic surgery procedures recommended
by most international scientific societies has been adopted by many surgeons worldwide and resulted in
a huge socioeconomic impact for most private practices and clinics. An important question still unan-
swered in most countries is when and how should elective/aesthetic procedures be scheduled again and
what kind of organizational changes are necessary to protect patients and healthcare workers when clinics
and practices reopen. Defining manageable, evidence-based protocols for testing, surgical/procedural risk
mitigation and clinical flow management/contamination management will be paramount for the safety
of non-urgent surgical procedures. METHODS We conducted a MEDLINE/PubMed research for all
available publications on COVID-19 and surgery and COVID-19 and anesthesia. Articles and referenced
literature describing possible procedural impact factors leading to exacerbation of the clinical evolution
of COVID-19-positive patients were identified to perform risk stratification for elective surgery. Based
on these impact factors, considerations for patient selection, choice of procedural complexity, duration
of procedure, type of anesthesia, etc., are discussed in this article and translated into algorithms for
surgical/anesthesia risk management and clinical management. Current recommendations and published
protocols on contamination control, avoidance of cross-contamination and procedural patient flow are
reviewed. A COVID-19 testing guideline protocol for patients planning to undergo elective aesthetic
surgery is presented and recommendations are made regarding adaptation of current patient informa-
tion/informed consent forms and patient health questionnaires. CONCLUSION The COVID-19 crisis has
led to unprecedented challenges in the acute management of the crisis, and the wave only recently seems
to flatten out in some countries. The adaptation of surgical and procedural steps for a risk-minimizing
management of potential COVID-19-positive patients seeking to undergo elective aesthetic procedures in
the wake of that wave will present the next big challenge for the aesthetic surgery community. We pro-
pose a clinical algorithm to enhance patient safety in elective surgery in the context of COVID-19 and to
minimize cross-contamination between healthcare workers and patients. New evidence-based guidelines
regarding surgical risk stratification, testing, and clinical flow management/contamination management
are proposed. We believe that only the continuous development and broad implementation of guidelines
like the ones proposed in this paper will allow an early reintegration of all aesthetic procedures into the
scope of surgical care currently performed and to prepare the elective surgical specialties better for a
possible second wave of the pandemic. LEVEL OF EVIDENCE V This journal requires that authors
assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings,
please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
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Abstract
Background The worldwide spread of a novel coronavirus
disease (COVID-19) has led to a near total stop of non-
urgent, elective surgeries across all specialties in most
affected countries. In the field of aesthetic surgery, the self-
imposed moratorium for all aesthetic surgery procedures
recommended by most international scientific societies has
been adopted by many surgeons worldwide and resulted in
a huge socioeconomic impact for most private practices
and clinics. An important question still unanswered in most
countries is when and how should elective/aesthetic pro-
cedures be scheduled again and what kind of organizational
changes are necessary to protect patients and healthcare
workers when clinics and practices reopen. Defining
manageable, evidence-based protocols for testing, surgical/
procedural risk mitigation and clinical flow manage-
ment/contamination management will be paramount for the
safety of non-urgent surgical procedures.
Methods We conducted a MEDLINE/PubMed research for
all available publications on COVID-19 and surgery and
COVID-19 and anesthesia. Articles and referenced litera-
ture describing possible procedural impact factors leading
to exacerbation of the clinical evolution of COVID-19-
positive patients were identified to perform risk stratifica-
tion for elective surgery. Based on these impact factors,
considerations for patient selection, choice of procedural
complexity, duration of procedure, type of anesthesia, etc.,
are discussed in this article and translated into algorithms
for surgical/anesthesia risk management and clinical
management. Current recommendations and published
protocols on contamination control, avoidance of cross-
contamination and procedural patient flow are reviewed.
A COVID-19 testing guideline protocol for patients plan-
ning to undergo elective aesthetic surgery is presented and
recommendations are made regarding adaptation of current
patient information/informed consent forms and patient
health questionnaires.
Conclusion The COVID-19 crisis has led to unprecedented
challenges in the acute management of the crisis, and the
wave only recently seems to flatten out in some countries.
The adaptation of surgical and procedural steps for a risk-
minimizing management of potential COVID-19-positive
patients seeking to undergo elective aesthetic procedures in
the wake of that wave will present the next big challenge
for the aesthetic surgery community. We propose a clinical
algorithm to enhance patient safety in elective surgery in
the context of COVID-19 and to minimize cross-contami-
nation between healthcare workers and patients. New evi-
dence-based guidelines regarding surgical risk
stratification, testing, and clinical flow management/con-
tamination management are proposed. We believe that only
the continuous development and broad implementation of
guidelines like the ones proposed in this paper will allow
an early reintegration of all aesthetic procedures into the
scope of surgical care currently performed and to prepare
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the elective surgical specialties better for a possible second
wave of the pandemic.
Level of Evidence V This journal requires that authors
assign a level of evidence to each article. For a full
description of these Evidence-Based Medicine ratings,
please refer to the Table of Contents or the online
Instructions to Authors www.springer.com/00266.
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Introduction and Background
The outbreak of a novel coronavirus disease in Wuhan,
China, in December marked the beginning of unprece-
dented global spread of the disease, leading to a near col-
lapse of the healthcare systems in most affected countries
[1].
In January 2020, the disease was declared a public
health concern of international scale by the World Health
Organization (WHO) and has been named COVID-19 in
February 2020, with SARS-Cov-2 being the name of the
causing virus. As the disease is highly contagious and
asymptomatic carriers make containment a difficult chal-
lenge, it has spread since around the globe with more than
1.5 million confirmed cases worldwide and nearly 100,000
confirmed deaths as of April 10, 2020 [2, 3].
Main transmission vectors were originally thought to be
respiratory droplets and direct contact; however, recent
publications suggest the possibility of aerosol propagation
as well [4–6].
Symptoms may appear 2–14 days after exposure and
period incubation ranges from 4 to 7 days, during which
any infected patient may be asymptomatic and contagious
[8].
The most common symptoms are fever (98%), anosmia
(80%), cough (76%), myalgia or fatigue (44%). About half
of the patients present dyspnea. (The median time from
onset to dyspnea was 8 days.) All have bilateral, interstitial
pneumonia identifiable by their characteristic distribution
patterns in chest computer tomography (CT) scans: ground
glass opacification (GGO) (88.0%), bilateral involvement
(87.5%), peripheral distribution (76.0%) and multilobar
(more than one lobe) involvement (78.8%). In the majority
of documented COVID-19 cases, the initial chest CT is
abnormal, even in some patients without any evident
symptoms. Follow-up CT in the intermediate stage of
disease shows an increase in the number and size of GGOs
and progressive transformation of GGO into multifocal
consolidative opacities, septal thickening, and development
of a crazy paving pattern, with the greatest severity of CT
findings visible around day 10 after the symptom onset.
Cardiac involvement and arrhythmic complications in
COVID-19-positive patients have been described [8–10].
In a cohort of 201 patients with COVID-19 pneumonia in
Wuhan, 84 (41.8%) patients developed ARDS, 53 patients
(26.4%) were admitted to an intensive care unit, 67 patients
(33.3%) received mechanical ventilation, and 44 patients
(21.9%) died. Forty-four (65.7%) patients who received
mechanical ventilation died. Patients developing ARDS were
older (difference, 12.0 years; 95% CI 8.0–16.0 years;
P\ 0.001) and had comorbidities, including hypertension
(difference, 13.7%; 95% CI 1.3–26.1%; P = 0.02) and dia-
betes (difference, 13.9%; 95%CI 3.6–24.2%;P = 0.002) [11].
In a study comparing European and US data on COVID-
19, individuals under 65 years old had 34–73-fold lower
mortality risk than individuals over 65 years old and
accounted for only 5–9% of all European COVID-19
deaths, with almost all deaths occurring in the range of
40–65 years. Data from three US locations suggest a
threefold higher death rate for the same group under
65 years old (30%).
In spite of representing 52–64% of the total age group
under 65 years, the subgroup under 40 years of age only
accounted for less than 1%of all EuropeanCOVID-19 deaths.
The large majority of the COVID-19-related deaths in
non-elderly individuals occurred in patients who suffered
from underlying diseases: cardiovascular disease, hyper-
tension, chronic obstructive pulmonary disease, severe
asthma, diabetes, kidney failure, severe liver disease,
immunodeficiency and malignancy [12].
Declared a global pandemic by the WHO on March 11,
the sudden surge of COVID-19 brought many affected
countries to the limit of their healthcare capacity. Health-
care workers, essential system resources and hospital care
space had to be reorganized and reserved for the high-
acuity care of COVID-19 patients, leading to a near full
stop of non-urgent, elective procedures in many countries
during the peak of the pandemic [13, 14].
Even without the existence of a legal ban or a declared
state of emergency in most affected countries, the scarce-
ness of resources like PPE during the peak of the pandemic,
the obvious necessity of liberating available care space in
hospitals and the risk of potential complications that could
occupy urgently needed ICU beds made it an ethically
necessary decision for most national and international
aesthetic surgery societies to recommend the temporary
stop of all aesthetic, non-urgent surgery [15–17].
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A growing number of articles are published at this
moment covering all aspects of contamination prevention,
elevated surgical risk and clinical management of COVID-
19-positive patients. The question remains if elective sur-
gery is still advisable on infected patients at all or should
be generally postponed [18, 19].
There seems to be a general consensus in the current
published literature on postponing elective, non-urgent
surgery on COVID-19-positive patients. But to our best
knowledge, so far no recommendations have been pub-
lished on when and how to start again carrying out elective,
non-urgent surgery on COVID-19-negative patients after
the epidemic peak has been reached in a given country or
region and the pressure on healthcare facilities, healthcare
workers and resources has been released by so far that
elective surgery procedures can be safely and ethically
programmed again.
The authors think that answering those two questions is
of great interest not only for the plastic surgery community,
but also for other surgical specialties performing highly
elective, non-urgent interventions on a daily basis, which is
why specialists from other elective surgery fields were
asked to co-author and share their perspective.
‘‘Nothing will be like before after this pandemic,’’ this
often-heard statement will be especially true for healthcare
providers and surgeons, as the virus will not completely
disappear from our societies once the first wave of the
pandemic is over [20].
The interventions put into place for virus containment,
like restriction of movement, measures to enforce physical
distancing, cannot be held in place for an unlimited time, as
socioeconomic necessities become more pressing and all
affected countries will have to work on a staged exit
strategy at a given moment. A study focused on the effects
of extending or relaxing physical distancing control mea-
sures in Wuhan has suggested that if the measures are
gradually relaxed in March, a second wave of cases might
occur in the northern hemisphere around mid-summer. The
same effect is expectable for all other countries at a later
date, meaning that the virus will prevail in society until a
vaccine becomes available [21–23].
Until then, as surgeons, we will have to learn to live
with a new reality, and we may have to adapt our clinical
workflow and to reformulate the way we care for patients.
This article aims to give some orientation toward this
important task and to serve as base for the formulation of
specific guidelines from healthcare providers and health-
care administrators.
The article’s first goal is to make a recommendation on
the time frame for the reintroduction of elective procedures
based on current healthcare strain projections, the health-
care resilience model and projections of virulence. The
second goal is to provide the scientific base for solid
elective surgery protocols which may be implemented in
the moment when a country or region meets the criteria to
implement elective, non-urgent procedures.
While we think that both questions can be answered
analyzing the plethora of peer-reviewed literature available
to date, the second one is much more complex. It involves
many variables that influence patient safety and healthcare
worker protection and additionally implies some general
reflections about risk assessment and risk acceptance in a
post-pandemic society.
Methods
We used a MEDLINE/PubMed research for all available
publications in English and Spanish up to April 20, 2020,
on COVID-19 AND Surgery, COVID-19 AND Anesthesia,
COVID-19 AND Screening, COVID-19 AND Medication
to identify existing protocols, preliminary reports on out-
comes and published recommendations on surgical care in
context with COVID-19. Articles and referenced literature
describing possible procedural impact factors leading to
exacerbation of the clinical evolution of COVID-19-posi-
tive patients were identified and classified. Based on the
most commonly discussed denominators, we defined six
subsets for the creation of guideline proposals for elective
surgery:
• Surgical risk management and risk stratifying
• Perioperative and anesthesia management
• Preoperative testing and screening
• Perioperative pharmacologic prophylaxis
• Clinical management and contamination control
• Patient information and patient consent
The proposed implementation of the recommended
guidelines for the six clinical subsets is shown in a general
clinical pathway protocol (Fig. 1).
Proposed Time Frame for Implementation
of Elective, Non-urgent Surgery Procedures
To give a recommendation on when elective aesthetic
procedures might become practically and ethically feasible
again after the epidemic peak has been reached in a given
country or region, we propose to use an approach based on
the evaluation of healthcare system strain in a given
country.
In the authors’ opinion, when the COVID-19-related
system strain on healthcare facilities, healthcare workers
and resources has diminished to levels where the available
healthcare resources (hospital beds, ICU beds, materials,
tests, PPE, etc.) meet the demand again with a stable pos-
itive margin, health administrators can start to plan and
Aesth Plast Surg
123
perform elective surgery procedures in hospitals and clinics
which have implemented post-COVID-19 protocols like
the ones that will be discussed in this article.
As the infection curve is flattening in a very similar
matter in Spain, Italy and Germany, with the USA, the UK,
France and Canada lagging around 4 weeks behind, it
becomes obvious that the actual strain on healthcare system
capacity should normalize within 4–10 weeks and the
above-mentioned limitations will gradually disappear.
Taking projections for Spain as example, around April 18
COVID-19-related demand for healthcare resources will
first drop below the availability baseline, resulting in a
Fig. 1 Flowchart clinical pathway
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positive margin with a stable reserve around April 26,
which could be considered by healthcare administrators as
possible date for re-implementation of elective procedures.
As availability of resources and strain on the healthcare
system may vary significantly between regions or even
between different healthcare structures locally due to some
areas being more affected than, the local conditions prevail
and may resume in staged reimplementation of elective
surgery throughout one country or nation. The American
College of Surgeons recommends using local prevalence
and incidence rates and to consider a decrease in measures
of COVID-19 incidence for at least 14 days before tran-
sitioning to provide surgical services for patients without
immediately life- or limb-threatening conditions [24, 25].
Figure 2 shows an example of COVID-19 healthcare
strain projections April 24, 2020, for Spain while assuming
continued full social distancing. The blue shaded area
marks the level of uncertainty of the healthcare strain
projection beyond April 24, 2020.
Using such normalization projections on healthcare
system strain, including needed/used ratio for ventilators,
ICU beds and normal beds may present an adequate
approach to decide on the timing when to gradually
implement elective surgery procedures into the healthcare
panorama.
How far after peak resource use the projected normal-
ization of these ratios occurs will vary largely from country
to country or even from one region to another in the same
country depending on healthcare system base capacity and
system resilience. Healthcare system resilience in the face
of a major health crisis is influenced by non-disease
immanent factors like governance, financing, service
delivery, availability of medicine and equipment, health
workers capacity and finally information flow [26].
Differences across countries in the successful control of
these factors and long-term underinvestment in health
services, as seen in many countries following the 2008
financial crisis, may impair their resilience by depleting
their ability to respond to surges and leading to a signifi-
cantly delayed normalization of healthcare strain.
Clinical Considerations for Reintegration
of Elective, Non-urgent Surgery Procedures
Once that the restrictions of movement for patients have
been loosened or lifted and decision has been made to
implement elective, non-urgent procedures, every specialty
department should thoroughly analyze their clinical and
surgical workflow and their procedure/specialty-related
risk profile and adapt their institutional clinical guidance
protocols for patient evaluation and procedure selection to
respond to the new post-pandemic challenges.
In the case of non-urgent elective procedures, especially
in the case of aesthetic procedures without a curative
indication, surgeons have to be aware that even with a solid
routine testing protocol in place for all elective patients
there is still a window of uncertainty due to test sensitivity
and incubations times [27–29].
As even asymptomatic contacts have shown to be pos-
sible transmission vectors, it is the authors’ group con-
sensus opinion that every patient should be managed as
potentially COVID-19 positive and that all clinical path-
ways regarding choice of treatment/procedure, pre- and
perioperative screening, type of anesthesia, medication,
contamination protection/decontamination and patient
information/informed consent need to be adapted to this
potential risk [30–32]. These measures should be kept in
place at least temporarily, until either the herd immunity is
achieved in large parts of the population, the virulence has
Fig. 2 Healthcare strain projection Spain
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significantly diminished or a vaccine is available. The
recommendations on the subset guidelines presented in this
article should not be seen and used as isolated clinical
pathways, but should be understood as closely interwoven
and influencing each other in significant key aspects. This
is why some aspects maybe discussed redundantly in the
different protocol sections, as they influence more than one
clinical decision pathway.
Clinical relevance high—evidence level: moderate
Considerations for Surgical Risk Assessment, Risk
Stratifying and Procedure Selection
There is evidence that the mortality of COVID-19-positive
patients undergoing surgery may be higher than the general
mortality of the disease, but to date only limited data are
available [8].
Aminian et al. reported a series of four surgical patients
(cholecystectomy, hernia repair, gastric bypass, and hys-
terectomy) who developed perioperative complications in
the first few weeks of COVID-19 outbreak in Tehran.
Three patients developed postoperative fever and pul-
monary complications after uneventful elective operations
and two patients died [33].
Lei et al. reported a series of 34 patients operated
electively during the outbreak. Their conclusion was that
surgery may accelerate and exacerbate disease progression
of COVID-19. Seven patients (20.6%) died of COVID-19-
associated complications (six–sevenfold higher overall
case-fatality rate than 2–3% in COVID-19 patients without
surgery. Fifteen patients (44%) were admitted to ICU, 13
of those (86.6%) had Level III surgeries, while the majority
of non-ICU patients were Level II surgeries.
Patients admitted to ICU had longer surgical time
(median time 200 min, P = 0. 04), were significantly older
(median age, 55 years vs. 47 years, P = 0. 03) and were
more likely to have underlying comorbidities such as
hypertension, diabetes and cardiovascular disease. All
patients that died had Surgery Level III, longer surgical
time and one or more comorbidities. No patient was tested
for COVID-19 preoperatively [34].
The proportion of patients receiving ICU care was
higher in this cohort (44%) than the reported 26% in hos-
pitalized COVID-19 patients without surgery [8].
Another patient series published by Li et al. from tho-
racic surgery department also suggests the association of
higher age and chronic obstructive pulmonary disease
(COPD) with disease severity (P = 0.041 and P = 0.040,
respectively) and death (P = 0.015 and P = 0.038,
respectively) for COVID-19 patients. In this study, five
deaths (20%) among hospitalized postoperative patients
were reported, leading to the conclusion that patients
infected with COVID-19 in the perioperative period have a
higher risk of death [7].
Clinical relevance high—evidence level: high
Surgical Risk Stratification
Based on the limited data evidence available at time of
writing of this article, age and presence of comorbidities
are primary factors in the prognosis of the disease. In
operated COVID-19-positive patients, higher surgical
severity Level, general anesthesia and longer duration of
surgery seem to correlate with an aggravation of clinical
outcome [33, 34].
That is why it must be ensured as much as possible that
a patient undergoing an elective operation is COVID-19
negative.
Elective aesthetic plastic surgery could be considered as
safe in most cases, due to an overall low morbimortality of
the patients, short duration of surgery and Level I–II sur-
gical complexity in most cases. Only a few procedures
have been linked to more severe problems (deep venous
thrombosis, pulmonary embolism, bleeding) such as large
volume liposuction, post-bariatric surgery and recently fat
grafting to buttocks, which was linked to a 7% rate of fat
embolism and 3% rate of mortality [35].
It is controversial if combining procedures are less safe
than isolated. Khavanin et al. reported the complication
rates among combined procedures (9.40%) were greater
than those of aesthetic breast surgery (2.66%; P\ 0.001)
but did not significantly differ from abdominal procedures
(9.75%; P = 0.530), while Kaoutzanis et al. reported a
major complication rate of 0.7% with hematoma (0.15%),
pulmonary complications (0.1%), infection (0.1%) and
confirmed venous thromboembolism (VTE) (0.06%) with
liposuction. Combined procedures had a higher risk of
confirmed VTE (RR 5.65), pulmonary complications (RR
2.72) and infection (RR 2.41) [36, 37].
Simon et al. found no significant increase in morbidity
between the control group and those patients who under-
went combined surgical procedures. Abdominoplasty
combined with other surgical procedures did not appear to
produce significant additional morbidity [38].
Surgical time could be an issue in terms of morbimor-
tality. Analyzing 1800 complex procedures, Krista et al.
concluded that surgeries resulting in complications had
longer operative times than those that did not (6.0 vs. 4.1 h,
P\ 0.0001). Postoperative complications were also asso-
ciated with obesity (P\ 0.001), male sex (P = 0.048),
diabetes (P = 0.0061), hypertension (P = 0.0078) and
renal comorbidities (P = 0.0096). Morbidity significantly
increased only after 3.13 h, with progressively greater odds
increases of 3.05 times after 4.52 h and 4.71 times after
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6.77 h. However, facelifts had long procedures times but
showed a low complication rate. Therefore, the surgical
complexity level has to be considered as important as
surgical time [39].
The surgical complexity level may be of importance as
well in the context of possible COVID-19? patients, as the
limited data published to date suggesting a higher postop-
erative morbimortality is based mainly on patients that
underwent Level III surgeries [34].
The complexity and surgical time most aesthetic plastic
surgery procedures could be considered as Level II. Only
combinations of various procedures and post-bariatric
surgeries would be considered Level III (Table 1).
Taking into account the evidence discussed above, all
these factors should be reflected in the clinical decision-
making algorithm for any patient planning to undergo
elective, no urgent surgery while we are still on the curve
of the epidemic. Little is known at time of writing this
manuscript if patients could have any long-term sequels
after a COVID-19 infection, especially for cases that nee-
ded mechanic ventilation during ICU admission. We do not
know yet if acquired immunity after infection is protective
and lasting, and asymptomatic carriers may be a major
problem for the time until a vaccine is available. Until then,
our objectives should be:
• To screen all patients to determine who could be
operated safely
• To protect negative COVID patients who undergoing
an elective operation
• To protect health personnel
Clinical relevance high—evidence level: high
Considerations for Perioperative and Anesthesia
Management
The criteria for patient selection, individual risk stratifica-
tion and testing during the preoperative consultations with
surgeon and anesthetist have been laid out in above
(Fig. 3).
Goal of this selection and testing protocol is to minimize
the risk to operate on a COVID-19-positive patient and to
exclude patients with comorbidities that are associated with
possible negative postoperative and post-anesthetic out-
come in case of getting infected in the perioperative period
[40–43].
The most common factors predicting a risk of a negative
post-anesthetic outcome in case of a perioperative COVID-
19 infection are [40–43]:
1. Age over 65 years




6. Cerebral vascular disease
7. Ischemic and valvular heart disease.
8. Cardiac arrhythmia
9. Diabetes mellitus




Pre-anesthetic consultation The main goal is to identify
and exclude symptomatic infected patients, asymptomatic
patients within the incubation period/asymptomatic carriers
and patients with the above-mentioned comorbidities. The
pre-anesthetic clinical record should identify the American
Society of Anesthesiologist (ASA) level, the comorbidities,
the functional classification and the use of medication
[44–46].
Only ASA1 and ASA2 patients with a normal functional
classification should be selected for elective, non-urgent
procedures [42, 43, 45].
The health questionnaire has to cover signs of acute
infection such as fever, dry cough, fatigue, sore throat,
anosmia, skin rash or other gastrointestinal symptoms such
as diarrhea, anorexia, vomiting, nausea, abdominal pain
and/or gastrointestinal bleeding [40, 42, 45, 48–53].
It is important to ask for use of any current or past
prophylactic/therapeutic treatment against COVID-19,
such as chloroquine and azithromycin, as they are related
to an increase in QT-time, which may consequently lead to
severe arrhythmia [54–56].
Blood pressure measurement should be included in the
standard preoperative workup protocol to exclude arterial
hypertension.
The standard preoperative laboratory workup should
include a full blood count to identify COVID-19-related
alterations such as leukocytopenia and lymphopenia as
well as coagulation tests, kidney–liver function and CRP
levels, as well as blood sugar levels to exclude diabetes
[40, 42, 47, 49, 50, 52, 57, 58].
The preoperative determination of D-dimers levels and
ferritin levels, which have been proven to be an indicator
for clinical outcome in COVID-19-positive patients, is
controversial in the case of negative-tested patients who are
planning to undergo elective surgery as published evidence
is still weak [47, 59].
Standard chest X-ray has a proven predictive strength
and may be included for all patients undergoing intubation
anesthesia [46, 47]
Low-dose chest CT scan has an even higher predictive
value for an active COVID-19 infection and may be
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performed in cases where other methods of COVID-19
testing are not available or inconclusive [47, 49, 50].
Clinical imaging should be analyzed for COVID-19-asso-
ciated peripheral, uni-/bilateral pulmonary infiltration pat-
terns that manifest consistently during the initial phases of
the disease [9, 10, 46, 47, 49]. The authors suggest that
these recommendations on diagnostic imaging are fre-
quently reviewed by the facility’s anesthesiology provider
and adaptations are made as soon as the other tests achieve
higher accuracy, better predictive power and wider
availability.
The limitations of sensitivity and specificity of the
currently available tests and the influence of the incubation
period on the predictive power of preoperative testing will
be discussed in the section on testing of this article. It is the
opinion of the authors’ group that all cases planned for
elective surgery during the descending curve of the disease
should be considered as potentially infectious, and there-
fore hospitals and other medical establishments should take
the appropriate precautions regarding the prevention of the
propagation of the disease, especially with regard to
patients residing in high-risk areas [45, 60].
Clinical relevance high—evidence level: high
2. Anesthetic process
Upon arrival to the hospital or the ambulatory surgery
center, it is essential to rule out again any signs suggestive
for COVID-19 infection. Patients must have their temper-
ature taken, use facial masks and undergo hand disinfection
before being admitted to the ward. In hospitals, separated
patient circulation pathways must be established for
negative tested patient coming for elective surgery and
non-tested/COVID-19-positive (confirmed or suspected)
cases.
Induction/Premedication
The rest of the preoperative medication, especially when
using either ondansetron or droperidol, must be used with
special precaution as there is a possible risk in the QT-time
as described above.
In the premedication, it is recommended to use pro-
phylactic antibiotics and antiemetic drugs [45]. In the lat-
ter, the use of ondansetron and droperidol is recommended
instead of the use of dexamethasone as it can increase the
risk of viral spread in COVID-19-positive patients, as well
as delay the elimination of the virus [45, 49, 53, 61–64].
Table 1 Levels of surgical complexity
Level I Minimal risk to the patient independent of anesthesia
Minimally invasive procedures with little or no blood loss
Often done in an office setting with the operating room principally for anesthesia and monitoring includes: breast biopsy, removal of
minor skin or subcutaneous lesions, myringotomy tubes, hysteroscopy, cystoscopy, fiberoptic bronchoscopy
Level II Minimal to moderately invasive procedure
Blood loss less than 500 cc
Mild risk to patient independent of anesthesia includes: diagnostic laparoscopy, dilatation, and curettage, fallopian tubal ligation,
arthroscopy, inguinal hernia repair, laparoscopic lysis of adhesions, tonsillectomy/adenoidectomy, umbilical hernia repair,
septoplasty/rhinoplasty, percutaneous lung biopsy, superficial aesthetic procedures
Level
III
Moderate to significantly invasive procedure
Blood loss potential 500–1500 cc
Moderate risk to patient independent of anesthesia includes: hysterectomy, myomectomy, cholecystectomy, laminectomy, hip/knee





Blood loss greater than 1500 cc
Major risk to patient independent of anesthesia includes: major orthopedic spinal reconstruction, major reconstruction of the
gastrointestinal tract, major vascular repair without postoperative ICU stay
Level V Highly invasive procedure
Blood loss greater than 1500 cc
Critical risk to patient independent of anesthesia
Usual postoperative ICU stay with invasive monitoring includes: cardiothoracic procedure, intracranial procedure, major procedure
on the oropharynx, major vascular skeletal, neurologic repair




After completion of the anesthesia checklist upon arrival
of the patient in the induction area or operating room,
monitoring and IV lines will be placed, and induction is
performed following the institutional protocols for the
chosen anesthesia technique [45, 62].
Regional/Tumescent Anesthesia with or Without
Sedation
Regional/tumescent with or without conscious sedation
should be regarded as the first and most important option
for elective surgery during the post-COVID-19 curve as it
avoids invasion of the tracheal–bronchial tract.
Fig. 3 Algorithm for risk stratification
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This anesthesia modality should be performed whenever
complexity of surgery and anatomic location allow, and
may include the following categories: neuraxial anesthesia,
ultrasound-guided peripheral nerve block and tumescent
anesthesia. The equipment used for visualization, such as
ultrasound probes, must be efficiently protected/isolated
and disinfected after use following the COVID-19 decon-
tamination guidelines discussed in this article
[41, 50, 65–67].
The anesthetist should use PPE including gown, gloves,
FFP2 facial masks and surgical cap. In cases that the
sedation has to be converted into general anesthesia, double
gloves, facial shield and/or goggles should be added
[41, 46, 51, 53, 66, 69].
If intravenous sedation is used in combination with
regional anesthesia for hemodynamic stability and/or
patient comfort, only conscious sedation must be attempted
in order to avoid respiratory depression and cough [67].
If oxygen is needed, it should be applied in low flow to
guarantee optimal hemoglobin oxygen saturation.
During this process, the patient must keep his surgical
mask on and gloves on in order to reduce the risk of
contamination, the oxygen should be applied over nasal
cannula under the surgical mask [45].
Sedation as an anesthetic technique has a higher risk of
major respiratory complications as well as a major risk of
contamination through aerosolized particles; therefore, the
technique should be avoided when treating COVID-19-
infected patients and used with precaution only on healthy
patients in elective cases. In cases in which the regional
anesthetic technique with sedation is not sufficient, the
procedure has to be converted to general anesthesia fol-
lowing the guidelines described in the following
[41, 45, 66].
If local anesthetic systemic toxicity (LAST) occurs,
treatment must occur in accordance with the guidelines of
the American Society of Regional Anesthesia and Pain
Medicine [65, 68].
General Anesthesia
In case of general anesthesia, the patient should be pre-
oxygenated with 100% oxygen over 5 min using a com-
pletely sealed facial mask. Manual bag ventilation should
be avoided in these cases [45, 66, 69–71].
Rapid sequence intubation (RSI) is recommended using
atropine/glycopyrrolate to reduce secretion, lidocaine,
propofol, rocuronium, as well as dexmedetomidine. Ideally
trans-oral endotracheal intubation (EI) with video laryn-
goscope should be used. Once the correct positioning of the
tracheal tube is established, it must be sealed immediately
by cuff inflation [41, 43, 45, 51, 53, 54, 66, 69, 70, 72–77].
The anesthetist should use PPE including long sleeved
gown, double gloves and FFP2 facial masks, goggles,
facial screen and surgical caps [41, 46, 51, 53, 66, 69]. To
avoid dispersion of particles, a drape forming a pocket can
be placed over the patients head during intubation.
In case of COVID-19-positive patients, the use of
laryngeal masks or supraglottic devices is controversial as
these could cause aerosolization of infectious particles and
therefore should be strictly reserved in cases of difficulties
in intubation or ventilation [45, 66].
In healthy, negative-tested patients undergoing elective
surgery, the use of these devices might be advantageous
due to lack of invasion of the tracheal–bronchial tract and
reduced ventilation pressure.
At time of writing of this article, it is unclear whether
intravenous anesthesia should be performed or whether
inhaled anesthesia should be favored [45]. The choice of
the applicable technique will be dependent on each case
and the conditions of the patient. The authors favor the
maintenance of the anesthesia with sevorane and
dexmedetomidine to limit the use of opiates, as they may
induce perioperative nausea and vomiting with a higher
risk of contamination through aerosols and coughing and
present a higher risk of immunosuppression [78]. The use
of low doses of neuromuscular blockers is also advisable
[69], thus avoiding the risk of postoperative respiratory
depression.
Ventilator setting should use a tidal volume between 4 and
8 ml/kg (optimal 6 ml/kg), with plateau pressure under
30 mmHg and 50% FIO2 to minimize the risk of atelectasis.
The use of positive end-expiratory pressure (PEEP) should
be optimized for adequate oxygen saturation level and pul-
monary recruitment. The use of extremely reduced or super-
high fresh-gas flow is contraindicated due to the risk of
contamination in the anesthesia machine and the operating
room. The exhalation gases must be connected to active
scavenging elimination system [45, 69, 70, 73, 76, 77].
To avoid spreading of infectious particles though the
anesthesia machine, the circuit should be equipped with
two HME filters, one of them located close to the patient
and the other filter located in the respiratory arm of the
machine. These filters and the breathing circuits, as well as
other disposables, should be discarded at the end of every
anesthetic case [45, 66, 74, 76, 79].
It may not be required to change the CO2 absorbers;
however, it is of great importance to change the CO2-
sample lines [61, 71, 74, 76, 79].
The combination of regional anesthesia described above
with general anesthesia can provide multimodal analgesia
effectively reducing the need for NSAIDs and opiates,
reserving the latter only for cases of analgesic rescue
[45, 63]. Although there is yet not enough evidence pub-
lished, the use of non-opiate general anesthesia could be
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beneficial for elective, non-urgent procedures in the post-
pandemic wake of COVID-19.
Extubating and Recovery
Once the surgical procedure is finished, the awakening of
the patient should be done gently using maneuvers which
reduce the risk of coughing, respiratory depression, nausea
and vomiting. To avoid this, the use of dexmedetomidine
and lidocaine is recommended. For extubation after EI, a
sterile drape can be placed over the anesthetist and the
patient to reduce contamination through aerosolization
during extubation; in sedation, the use of surgical masks is
essential for avoiding viral dispersion. Furthermore, the
reversal of neuromuscular blocks using pharmacological
antagonists as sugammadex is recommended. The use of
neostigmine must be avoided due to the risk of increasing
the secretion [45, 60, 69, 72, 75, 77].
The protection of the healthcare staff should be main-
tained by the use of double gloves, facial masks, goggles,
during extubation, and presence of staff kept to minimum
necessary. After the patient has been transferred to the
recovery unit and later to the ward, all medical/intubation
equipment, anesthesia stations and all surfaces in operating
rooms and in recovery rooms have to be decontaminated
following the recommendations laid out in the section
Contamination Management of this article
[40, 46, 47, 61, 79].
In the recovery room, it is essential to deliver the
required supportive care while assuring the hemodynamic
and respiratory stability and ensuring temperature control
[45].
The same regional anesthesia techniques as described
above can be used as the first step in the multimodal
anesthesia to achieve effective pain control why reducing
the need for NSAIDs and opiates. Low-dose flow of oxy-
gen should be used if needed.
Clinical relevance high—evidence level: high
Considerations for Preoperative Testing
and Screening
During the height of the pandemic, the decision to test
patients for COVID-19 was based on clinical and epi-
demiological factors and linked to an assessment of the
likelihood of infection [80]. Symptomatic patients or
mildly symptomatic patients were tested if they had contact
with a COVID-19 case. In the scenario of planning elective
surgical procedures in the aftermath of the pandemic,
where many patients may still be at risk of infection, may
be infected but asymptomatic or are immune to the con-
dition, it is prudent to engage a screening protocol to
optimize safety for both patient and health workers. We
assume that only patients should be considered for elective
procedures that are asymptomatic and have not been
exposed to infected individuals in the past 14 days. In order
to evaluate their infectious status, preoperative testing for
COVID-19 is mandatory.
At the time of writing this paper, many aspects of the
virus and COVID-19 disease are not fully understood, and
diagnostic tests for the virus are being developed, validated
and optimized. In the preoperative planning, surgical
patients should undergo a combination of molecular and
antibody-based serological tests. The two most commonly
used assay groups are being described briefly:
Reverse-Transcriptase Polymerase Chain Reaction (RT-
PCR) Tests
PCR is a very common molecular scientific technique that
has been widely used in research and medicine for many
years to detect genetic information. RT-PCR is a special
version used when RNA is being detected and it is now
being used as a test to detect SARS-CoV-2, the virus
causing COVID-19. Nucleic acid amplification tests
(NAAT) of respiratory secretions using the real-time
reverse-transcriptase polymerase chain reaction have been
proven to help identifying the virus in the early disease
stages by detecting unique sequences of virus RNA [81].
Availability of different assays using the RT-PCR tech-
nology has helped in patient detection and efforts to con-
tain the virus, since it detects presence of virus very early
in the infection [82].
RT-PCR tests are quick, sensitive and reliable, capable
of producing results in a few hours in a local laboratory,
although this may take longer if samples must first be sent
to specialized external laboratories. Many diagnostic and
research companies produce RT-PCR products, tests and
machines, so the technology is widely available and is
becoming cheaper. Some RT-PCR tests are developed as
an ‘‘all-in-one’’ kit, reducing laboratory handling and
potential for contamination [83].
The first step in any diagnostic coronavirus test is to get
a good-quality sample. A sterile swab/brush is passed
through the nose into the nasopharynx or through the oral
cavity to the oropharynx and left for several seconds to
absorb secretions [84]. The test may be uncomfortable for
the patient as it may irritate the nasal passage or the uvula.
Although a simple throat swab will provide sufficient
sensitivity to detect an early stage of infection [85], a total
of two swabs of the upper respiratory secretions (na-
sopharyngeal or oropharyngeal swab) or lower respiratory
specimen (sputum) are recommended to improve the
specificity of the test [86]. A common criterion for dis-
continuation of transmission-based precautions is a
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negative RT-PCR result from two sets of nasopharyngeal
and throat swab specimens on two consecutive days [87].
Other means of collecting samples are from saliva,
bronchial lavage, or stool.
Because a lot of recent research and development has
gone into RT-PCR assays used for COVID-19, results that
took days or a few hours to process are now available in
minutes. Most molecular tests have been approved by the
United States Food and Drug Administration (FDA) under
emergency use authorization and are Conformité Europé-
enne (CE) marked [88]. These molecular RT-PCR assays
are fairly reliable if performed on a sample taken from an
infected part of the body during active infection, with a
very high sensitivity and specificity [89]. A positive test
result means that patient tested as a current, active
infection.
A negative PCR result can mean that the person is truly
not currently infected by this virus, or presents a false-
negative result because the virus is not present at the sites
where the sample was taken from, or the sample taken was
of poor quality or too small, or that it is too early/too late in
the infection to detect virus RNA. Other reasons for false-
negative results could be laboratory handling errors or
technical reasons [86, 90].
During the height of the pandemic, chest computerized
tomography (CT) scans acted as a complementary diag-
nostic tool enabling physicians to effectively detect
COVID-19 infection in several RT-PCR false-negative
cases [91]. In the elective surgery scenario, negative test
results require new patient samples to be taken a week later
to further reduce the chance of missing an infected person.
The RT-PCR test cannot detect if a person has had the
virus and then cleared it after the end of the COVID-19
disease, i.e., whether a person had the disease, as it only
detects when active virus is present. The authors group
therefore recommends adding an antibody test to the pre-
operative workup.
Clinical Relevance of RT-PCR Tests
Patients with COVID-19 have demonstrated high viral
loads in the upper respiratory tract soon after their infec-
tion, with the highest load assumed to be the day before
symptoms appear. Therefore, the asymptomatic patient
carrier contributes to the rapid and wide spreading of the
virus.
Considering a mean incubation period of about 5 days,
infectiveness of a patient will start 2–3 days before
symptom onset, with the peak 1 day before symptom onset
[92]. Studies show that viral shedding is highest when the
viral load is at its peak, and gradually decreases within
7 days as patients’ progress through the course of their
disease, slowly reaching their detection limit about
3 weeks later [93].
Figure 4 shows a schematic representation of the evo-
lution of SARS-COV-2 virus and antigen; however, recent
evidence points to a possible shift of the peak of the curve
toward the left, which would indicate an earlier peak than
represented in the diagram. Further evidence and more
studies are needed to confirm these findings.
RT-PCR tests have proven to be valuable in establishing
a diagnosis of COVID-19 with high sensitivity and speci-
ficity. In addition to these diagnostic tests that are used to
confirm the presence or even viral load, antibody tests can
help to determine whether or not someone was previously
infected even if that person was asymptomatic [94].
Clinical relevance high—evidence level: high
Antibody or Antigen Tests (Lateral Flow Tests and ELISA)
Several different serology immunoassays based on anti-
body or antigen detection are currently available and are
used to complement the molecular assays of RT-PCR for
the diagnosis of COVID-19. The most prominent
immunoassays are rapid lateral flow immunoassays (gen-
erally called rapid diagnostic tests (RDTs) and manual
enzyme-linked immunoassay (ELISA). They are crucial to
identify viral reservoir hosts and patients who have become
immune to the disease [88]. Serological tests are cheaper to
perform than RT-PCR, with falling prices to be expected as
more companies get official approval for their products.
Lateral Flow/Rapid Diagnostic Test (RDT)
Rapid point-of-care immunoassays have been developed
using lateral flow technology to detect antigens of the
SARS-CoV-2 virus and detecting antibodies (IgM and IgG)
produced by COVID-19-infected patients. This qualitative
assay is small and portable, often resembling a pregnancy
test, showing the user colored lines to indicate positive or
negative results. These tests may use blood samples from a
finger prick, saliva samples or nasal swab fluids. RDTs do
not measure the quantity of antibodies in the patient serum,
or if these antibodies are able to protect against future
infection [95], but they have the ability to detect a passed
infection and can identify people who were asymptomatic
and people who cleared the virus and are no longer at high
of risk being infected or of spreading the virus.
The accuracy of results obtained by some rapid tests
correlates well with that achieved by RT-PCR. However,
since lateral flow antibody tests can be produced quickly
and cheaply, many such tests have come onto the market
recently. Many tests available to date lack analytical
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performance regarding sensitivity/specificity and need to
be tested and validated before getting approval.
Antigen lateral flow immunoassays present a newer
technology with additional scientific and technical chal-
lenges, which mean they are not likely to be fully devel-
oped during the pandemic period. These antigen assays
detect the virus directly without the amplification steps
needed for RT-PCR, and like those they are only able to
detect current active viral infection [83]. Another testing
concern is the variability of viral loads in COVID-19
patients, leading to false-negative antigen detection due to
low viral load or sampling variability [96]. Lateral flow
tests are more expensive and time-consuming for large
batch testing than laboratory-based antibody tests such as
ELISA.
Enzyme-Linked Immunosorbent Assay (ELISA)
An ELISA is a common biochemical technique used to
detect antigens or antibodies, depending on the type of test
used. This test can be qualitative or quantitative and is
generally a laboratory-based test often taking several hours
for results to be available. These tests usually use whole
blood, plasma or serum samples from patients. The test
relies on a plate that is coated with a viral protein of
interest, such as the spike protein. Patient samples are then
incubated with the protein, and if the patient has developed
COVID-19-specific antibodies (IgG and IgM), they bind
together. The bound antibody–protein complex can then be
detected with another wash of antibodies that produce a
color or fluorescent-based readout. It is a cheap and time-
effective method for batch testing of large numbers of
patient samples at the same time.
A positive ELISA test will indicate that the patient has
seroconverted (produced antibodies to the infection) and is
either currently infected, or has had an infection in the past.
A negative test would mean that the patient has not been
infected, or did not develop an immune response yet.
Neutralization Assay
This test examines the ability of antibodies to prevent viral
infection of cells in in vitro setting and is usually used to
confirm whether a positive antibody test is specific to the
investigated pathogen in question. Neutralization assays
are used to prove if a patient has antibodies that are active
and effective against a given virus, even if the patient has
already passed the infection. These tests require whole
blood, serum or plasma samples from the patient. Neu-
tralization assays depend on cell culture, a laboratory-based
method of culturing cells that allow SARS-CoV-2 growth.
Virus and cells are cultivated with decreasing concentra-
tions of antibodies to quantify how many antibodies in the
patient serum are able to block virus replication. This assay
is more important for understanding how antibody tests can
be qualified and quantified, and only plays a minor role in
the pre-op preparation of patients. Validation and
improving sensitivity and specificity of antibody assays are
important to limit cross-reactivity. Similar protein struc-
tures to other coronaviruses are responsible for this and can
lead to false-positive results [90, 97]. These are then further
tested and improved with the neutralization tests [98].
A lot of research is currently being conducted to
improve serological antibody tests, which will be more
accurate to detect COVID-19 infection or immunity. The
sensitivities of currently available assays are further
Fig. 4 Antigen/antibody curve
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validated [93], and new tests with higher accuracy may
become available soon.
Clinical Relevance Serological Antibody Tests
It has been shown that patients with COVID-19 infection
showed serological responses, including COVID-19 virus-
specific IgM and IgG [85]. IgM antibody can be detected as
early as day 3 in many infections. Seroconversion (de-
tectable antibodies) in a patient cohort in Germany with
mild COVID-19 symptoms occurred in half of all patients
by day 7, and in all by day 14 [84]. An Italian paper
showed that serological rapid tests are not useful for
diagnosing COVID-19 in the acute setting [29], when the
RT-PCR is more useful. Other studies showed that IgM is
detectable in samples from 10 to 30 days after SARS-CoV-
2 infection, while IgG can be detected from 20 days
onward [89]. The IgM response occurs earlier than that of
IgG, but then decreases and disappears. While IgG can
persist after passed infection for a long time, their protec-
tive role in case SARS-CoV-2 is still under investigation
[88]. Although it appears that recovered COVID-19
patients have antibodies for at least 2 weeks, long-term
data are still missing, and it is suggested that antibodies
might be present in the blood sample for many months to
years. Figure 4 shows this response schematically. More
results from current and future studies need to be evaluated
in order to improve the accuracy of the diagram shown in
relation to COVID-19.
IgM responses are notoriously non-specific, and given
the time required to develop specific IgG responses,
serology detection is not likely to play a major role in
active case management except diagnose/confirm late
COVID-19 cases, to determine the immunity of healthcare
workers, or used as a risk stratification to identify patients
for elective surgery [96].
Clinical relevance high—evidence level: high
Recommendations on Testing for Elective Surgery
Patients
During initial consultation, patients will be stratified
according to their risk profile, and the level of operation
planned is identified. They will be informed that preoper-
ative testing for COVID-19 will be necessary in order to
proceed with surgical planning.
All elective patients should be tested prior to scheduling
surgery in order to make sure that only patients without
COVID-19 infection will undergo a procedure. Since all
patients can be potential carriers of the virus, we propose
the following protocol, designed to protect both patients
and medical staff. The basis of the guideline is to identify
and rule out patients who might be in the asymptomatic
window period but are already infected with the virus. For
this, we suggest to perform staged testing at two separate
time points:
The first-line testing should include a RT-PCR test, as
well as a serological RDT for IgM and IgG antibodies
during routine preoperative workup. Ideally performed
1 week before the planned procedure, adaptation to local
conditions and pre-op pathways may be necessary. The
second-line testing should include another RT-PCR
48–72 h before the surgery. An additional serological rapid
diagnostic test (RDT) may be optionally performed at time
of admission. Before implementation, healthcare adminis-
trators may have to adapt the proposed timeline to the
clinical workflow of their facility.
Such a testing array will identify all patients already
infected before the pre-op workup day, but presented a
false-negative RT-PCR and still negative antibody tests at
the time of pre-op. These patients should test positive for
RT-PCR and/or for antibodies a week later, since most
studies support a median incubation time of 5–6 days. This
protocol will also identify patients who are infected but
completely asymptomatic.
Patients who pass both RT-PCR tests should be
requested to self-isolate in their homes during the follow-
ing 24–48 h prior to the surgery with special precautions to
prevent potential infection by family or friends. Wearing a
facemask when coming to the hospital/clinic and enforcing
social distancing at all times is strongly recommended.
RT-PCR Results
Patients testing positive for the RT-PCR tests at any stage
should be isolated and referred to the COVID-19 response
team, as this will indicate an active infection.
If the RT-PCR tests are negative on both occasions, the
patient can be operated following the second test, while
adhering to standard operating health and safety protocols
in theater. Any further investigations will depend on the
patient’s medical history, surgeon’s preference and planned
procedure.
Serological Antibody Results (RDT)
Positive antibody tests have to be qualified if they are
positive for IgM or IgG, or both.
If both initial IgM and IgG tests are negative, the patient
will be prepared for surgery and tested again 24–48 h prior
to the surgery at least 1 week later using the RT-PCR test
and RDT. If the PCR is negative and IgM test is positive,
the patient may still undergo the surgical workup. The
retest after 1 week will determine whether the surgery may
take place or not. If the PCR is negative and IgG test is
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positive, the patient may undergo the surgical workup since
it indicates passed infection. All further scenarios of pos-
sible result combinations of RT-PCR and RDTs are sum-
marized in Table 2.
Clinical relevance high—evidence level: moderate–high
Testing Recommendations for Health Workers
Involved in Elective Operations
In the literature, there are various recommendations on how
medical staff who were involved in surgical procedures
with COVID-19 patients should be tested. Some were
required to have a SARS-CoV-2 virus detection test (RT-
PCR of nasopharyngeal swabs) and CT scans once every
2 weeks [99], while others tested front-line workers with
RT-PCR tests only when they were symptomatic [100]. We
recommend regular testing of all staff involved in patient
care in the post-COVID-19 context using RT-PCR tests
whenever HCW shows COVID-19-associated symptoms,
and monthly RDTs for possible antibody responses.
Depending on local protocols and national reporting
requirements, both positive and negative results should be
reported to the national authorities.
Clinical relevance high—evidence level: moderate
Considerations on Perioperative Pharmacologic
Prophylaxis
Since every major surgical intervention results in stress for
the patient’s body and immune suppression during the
postoperative recovery may occur, a patient undergoing
elective surgery should to be as well prepared as possible,
especially during the descend of the pandemic curve
[101, 102].
In addition to the preoperative standard blood analysis,
it could be considered to include vitamin C and D levels,
zinc and blood iron levels and thyroid hormones (T3 and
T4) in the preoperative workup. If alterations of any kind
are detected, they should be corrected before the patient
undergoes elective surgery. In case of major procedures
(Level II or[ 2 h), a probiotic treatment can be initiated
2 weeks before the planned procedure to regulate the bal-
ance of intestinal micro biota and reduce the risk of sec-
ondary infection due to bacterial translocation in possible
COVID-19 patients [103].
Vitamin B12, copper, folate and selenium also play an
important role in the immune system response and there-
fore could also be tested [104, 105].
Vitamin D and curcumin have both shown positive
effects on the intestinal microbiome, in particular the
lactobacilli, which synergistically support probiotic therapy
[106, 107].
Data on efficient preventive medications in the context
surgery and COCID-19 are still limited; but we believe an
optimal preparation of every patient for planned, non-ur-
gent surgery during the curve and until the availability of a
vaccine.
The most relevant supplements and medications are
listed below in the order of clinical relevance for a possible
preventive treatment approach. The evidence of current
publications is still scarce, and larger clinical trials are
needed in the authors’ opinion before formulating strong
clinical guidelines for the perioperative use of those
substances.
Vitamin D
Vitamin D is known to mitigate the scope of acquired
immunity and regenerate endothelial lining. This may be
beneficial in minimizing the alveolar damage caused in
ARDS. One study showed that there is a 12% overall
protective effect of vitamin D supplementation against
bacterial and viral acute respiratory tract infection. These
protective effects increased to 19% in those individuals on
the daily or weekly regimen of vitamin D compared to
those dosing on a monthly bolus of vitamin D. Further-
more, there is a 70% protective effect when vitamin D
deficiency is corrected with supplementation. This result is
relevant to the majority of individuals residing in low-
sunlight countries that experience vitamin D deficiency due
to extended periods of lack of sunlight [108]. Therefor, low
vitamin D levels may also be expected during the first
phase after confinement ends.
In addition to the general immune system strengthening
properties of vitamin D, the expression and functionality of
ACE2 are reduced by vitamin D, reducing the virus’s
ability to dock on the cell. Furthermore, vitamin D alle-
viates lipopolysaccharide-induced acute lung injury via
regulation of the renin–angiotensin system (RAS) [109].
The vitamin D substitution should always go along with the
intake of magnesium in order to achieve a higher absorp-
tion rate or being better protected against over-dosing
[109]. Vitamin D levels should be checked on a regular
basis after being supplemented.
Clinical relevance level: high—evidence level high
Curcumin
Another interesting treatment approach is the perioral
substitution of curcumin. Curcumin is a bright yellow
chemical produced by Curcuma longa plants. It is the
principal curcuminoid of turmeric (Curcuma longa), a
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member of the ginger family, Zingiberaceae. Chemically,
curcumin is a diarylheptanoid, belonging to the group of
curcuminoids, which are natural phenols responsible for
turmeric’s yellow color. It can cause side effects, such as
nausea, diarrhea, hives, or dizziness. Interestingly, the
expression of TMPRSS2 is inhibited by curcumin. This
means that with the intake of curcumin, in addition to its
properties that fundamentally support and promote the
immune system and its overall anti-inflammatory proper-
ties, curcumin may also have a specific anti-COVID-19
property. Further clinical trials are needed to verify this
theory [110, 111].
Clinical relevance level: moderate/high—evidence level
low
Vitamin C
Regarding prevention with Vitamin C (L-ascorbic acid),
there is no evidence so far that taking vitamin C will help
prevent infection with the SARS-CoV-2. Vitamin C is an
important nutrient that keeps your immune system func-
tioning properly. It stimulates neutrophil chemotaxis and
contributes to maintaining the redox integrity of cells
thereby protecting them against reactive oxygen species.
Eating a variety of fruits and vegetables is recommended to
cover the daily demand.
Additionally, a recent meta-analysis showed that both
oral and IV high-dose vitamin C treatment may aid people
admitted to intensive care units (ICU) for critical illnesses
by reducing ICU stay length by 8% and shortening the
duration of mechanical ventilation by 18.2% [112].
In a scientific study focusing on patients with sepsis and
ARDS, a 96-hour infusion of vitamin C compared with
placebo could not significantly improve organ dysfunction
scores or alter markers of inflammation and vascular injury
[113].
Another study came to the conclusion that regular pro-
phylactic intakes of vitamin C at doses of 200 mg or more
daily have no effect on the incidence of the common cold,
but may be beneficial in the reduction of the severity and
duration of the symptoms, suggesting that vitamin C plays
some role in the respiratory defense mechanisms. There-
fore, elder patients, who have been shown to have a low-
ered vitamin C status and may therefore be more prone to
infections, persons exposed to continuous oxidative stress
like chronic smokers, and persons exposed to heavy
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physical exercise and/or cold environment may benefit
from a moderate continuous vitamin C intake.
While standard doses of vitamin C are generally harm-
less, high doses can cause a number of side effects,
including nausea, cramps, diarrhea and an increased risk of
kidney stones [114].
Further investigations are needed in order to assess if
vitamin C has a positive impact on preventing COVID-19.
Clinical relevance level: moderate—evidence level high
Zinc
Adequate steady intakes of zinc and vitamin C are essential
since the body has no storage system for these two sub-
stances. Both supplements have profound effects on cel-
lular growth and cell differentiation and have shown to be
vital for the optimal functioning of the immune system.
Zinc is important in cellular growth and differentiation
with profound effects on antioxidant defense, collagen
synthesis and the immune system. Zinc deficiency is
associated with impairment of cellular mediators of innate
immunity such as phagocytosis, natural killer cell activity
and the generation of oxidative burst [114].
Zinc salts as lozenges have been investigated for their
potential therapeutic effect on the common cold on basis of
their suggested direct antiviral activity. Available trials on
the effects of oral administration of zinc salts reported
conflicting results, and the available evidence is inconclu-
sive. However, a recent therapeutic trial with zinc acetate
showed a significant reduction in the overall duration of
symptoms and overall severity score. The discrepancies in
clinical outcome with zinc salts on the common cold have
recently been suggested to be due to a difference in zinc
ion availability to the oral and oropharyngeal mucosal
membranes in different formulations. Therefore, more
studies are required, especially with zinc acetate [114].
No direct prevention effect on COVID-19 virus.
Clinical relevance level: moderate/low—evidence level
low
Chloroquine and Hydroxychloroquine
Chloroquine, as well as the less toxic metabolite hydrox-
ychloroquine, has a long history in the prevention and
treatment of malaria and the therapy of certain inflamma-
tory conditions including systemic lupus erythematosus
(SLE) and rheumatoid arthritis (RA). In viruses, the two
medications can inhibit pH-dependent stages of replication.
Additionally, hydroxychloroquine/chloroquine’s
immunomodulation is dependent on the suppression of
cytokines (IL-6 and TNF-a) production and dissemination.
Both substances are currently under investigation in clini-
cal trials for pre-exposure or post-exposure prophylaxis of
SARS-CoV-2 infection [115].
Chloroquine inhibits SARS-CoV-2 in vitro with a half-
maximal effective concentration. Hydroxychloroquine has
a lower in vitro activity for SARS-CoV-2 compared with
chloroquine after 24 h of growth. No high-quality evidence
exists for the efficacy of chloroquine/hydroxychloroquine
treatment of SARS or MERS. Secondary COVID-19 rates
have shown to be reduced by hydroxychloroquine as pre-
and post-exposure prophylaxis in patients with documented
exposure to SARS-CoV-2, making it a candidate for
chemoprophylaxis of secondary COVID-19 [115].
At the moment, there is a lack of clinical trial data. In
the future, it could be discussed as preventive treatment
approach for older patients, patients with comorbidities or
patients with need for major surgery currently excluded in
our guidelines for elective surgery. Clinical trials are nee-
ded to verify the validity of this approach; currently, trials
for the use of hydroxychloroquine for post-exposure pro-
phylaxis in healthcare workers are enrolling. Chloroquine
and hydroxychloroquine are relatively well tolerated as
demonstrated by extensive experience in patients with SLE
and malaria. However, both agents can cause rare and
serious adverse effects (\ 10%), including hypoglycemia,
QTc prolongation, neuropsychiatric effects and retinopathy
[115].
Clinical relevance level: low—evidence level low
Ivermectin
Ivermectin belongs to the group of avermectins. It is
administered in the case of infestation with nematodes and
itch mites. The effects are due to the binding to chloride
channels, which leads to paralysis and death of the para-
sites. The anti-parasitical drug ivermectin almost com-
pletely eliminated SARS-CoV-2 in an in vitro model
within 48 h. Further investigations in a clinical trial setting
are needed to verify these results, and we do not recom-
mend this drug for preventive approaches at date [116].
Clinical relevance level: low—evidence level low
Treatment Options for Postoperative Patients
Testing Positive for COVID-19
If a patient should develop symptoms compatible with
COVID-19 during the perioperative period, he should be
referred immediately to a COVID-19 specialist team for
further diagnostics and treatment.
Most patients with COVID-19 will be able to recover at
home with symptomatic-orientated treatment, the WHO
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guidelines recommend acetaminophen (paracetamol) as
first-line antipyretic [108].
If shortness of breath appears, a supply of oxygen is
helpful and should be applied in a hospital setting to allow
for further diagnostics and treatment response in case of
clinical aggravation [117].
New treatment approaches are emerging and may be
available in the future, recent data suggest promising
results with nucleoside inhibitor drugs like remdesivir.
While safety and pharmacokinetics have already been
proven in various studies, remdesivir is currently not FDA-
approved for COVID-19 treatment; clinical trials are cur-
rently enrolled to evaluate the safety and antiviral activity
[115, 126].
Clinical relevance level: low—evidence level low
Considerations on Clinical Management
and Contamination Control
Clinical management, control of patient flow and contam-
ination control are essential to a safe working environment
in the wake of the COVID-19 pandemic and have to be
protocolized before restarting clinical practice.
Given our inability to use clinical symptoms or signs to
evaluate actual risk of transmission, any patient (whether
symptomatic or asymptomatic) must currently be consid-
ered potentially infected. This uncertainty is related to the
current lack of evidence to answer the question if aerosols
generated during procedures for examination or treatment
are to be considered infectious [118]. The underlying
assumption should be that every patient is potentially
infected with COVID-19 until proven otherwise. This
assumption is based on the growing community spread of
COVID-19 requiring ruling out infection before treatment.
Although some publications suggest that basic level PPE
for protection healthcare workers (HCW) should be suffi-
cient, it is the authors group opinion that, as screening
sensitivity and specificity are limited with tests available to
date, all patients and HCW should be treated as possible
carrier even for low-risk procedures [119]. This article
proposes a clinical circuit encompassing patient flow and
contamination prevention of all clinical areas and explains
the necessary steps to take for patients and HCW to per-
form safely in a COVID-19-free zone.
Such a circuit may be implemented easier in indepen-
dent ambulatory surgery centers (ASCs) or specialty clinics
than in hospitals, as the patient flow for primary care and
emergency care is harder to control. Hospitals will have to
adapt their structure creating COVID-19 and non-COVID-
19 areas to implement the proposed circuit. The guidelines
we propose are based on published evidence and cover the
use of personal protective equipment (PPE), surface
cleaning protocols and regulation of patient flow in order to
work effectively without overconcern and overuse of the
limited resources available at the moment. To minimize the
risk of averted contamination through asymptomatic car-
riers, a pre-visit questionnaire is very important (Table 3)
[119, 120].
The authors group consensus recommendations regard-
ing patient flow, HCW hygiene, PPE and decontamination
are found in ‘‘Appendix 1’’ of this article. We reviewed
current data on COVID-19 transmission in the hospital and
nonhospital settings [121–124]. PPE recommendations are
based on existing published data and assessments of
additional operating room risk during other viral epidemics
(SARS and Ebola virus disease) [125–127]. Clinical fea-
sibility was assessed by feedback from all participants in
this study.
Clinical relevance level: high—evidence level high
Recommendations on Garment (PPE)
Airborne transmission may occur when smaller respiratory
particles (generally\ 5 lm) circulate in the air for pro-
longed periods. Viral particles can be absorbed via the
respiratory mucosa and potentially across the conjunctivae.
Particles smaller than 10 lm are most likely to penetrate
deeply into the lung and cause infection. Existing data on
SARS-CoV-2 regarding airborne transmission available to
date suggest that social distancing is considered safe as
long as a minimum distance of 1.5–2 m can be kept [128].
However, certain examinations and procedures—par-
ticularly those associated with treating or examining the
face and neck—are susceptible to create aerosols by air
acceleration across a fluid surface. These aerosols con-
taining virus may linger in the air for a prolonged time and
therefore bear risk of transmission independent from a
physical security distance. Whether microdroplets have
real infective potential depends on effective viral load and
other factors and available data on SARS-CoV-2 in that
sense are still inconclusive [129–132].
The authors group recommends wearing PPE during
procedures where it is impossible to maintain social dis-
tancing and the HCW needs to work close to the face or
mouth and until the room is cleared of aerosol (the viral
clearance period) [133].
The use of masks is essential to protect general popu-
lation and HCWs. Filter efficiency depends on material and
sealing in classified by of FFP Level. FFP1 has a 80%
clearing capacity, FFP2 up to 94% and FFP3 up to 99%
including airborne (\ 5 microns) and microdroplets ([ 5
microns). Surgical masks retain only macrodroplets and
have less 80% filtration efficacy [134, 135].
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The recommended use of PPE classed by clinical
activity and the possible max. recommended reiterate use
are shown in Fig. 5.
Clinical relevance level: high—evidence level high
Recommendations on Decontamination
and Cleaning
Different methods can be chosen for the disinfection of
hands and surfaces. Ultraviolet (UV) disinfection, hot
water bath with temperature of[ 56 C (132.8 K) for
30 min, chlorine-containing disinfectants, peracetic acid or
75% ethanol can effectively inactivate the virus [136–138].
For hand decontamination, we suggest using the rule of
seven: performing hand disinfection before and after any
aseptic procedure, touching a patient, changing clothes,
change in clinical area, eating/drinking, bathroom use,
leaving/arriving clinic.
Facial masks and FFP respirators have shown the
potential of for decontamination either through short steam
cycles or dry heat, but more studies are needed to confirm
these recommendations [139, 140].
The authors’ group recommendations on decontamina-
tion of PPE, instruments and surfaces are summarized in
‘‘Appendix 1’’
Clinical relevance level: high—evidence level high
Considerations for Patient Information and Patient
Consent
As discussed before, surgical/clinical outcome may be
affected by a COVID-19 infection during the perioperative
period [33, 34].
Even after implementing a clinical pathway protocol
like the one proposed in this article (Fig. 1) and using an
algorithm for surgical risk reduction an stratification
(Fig. 3), it is the authors group opinion that specific
COVID-19-related information should be transmitted to the
patient and that patients should be required to sign an
addendum consent form for COVID-19-associated risks
known to date in the context with elective surgery.
Proposed models for a COVID-19-related patient
information sheet and for a COVID-19-specific consent
form are presented in ‘‘Appendix 2’’ and ‘‘Appendix 3’’ of
this article.
Conclusion
The COVID-19 crisis has led to unprecedented challenges
in the acute management of the crisis, and the wave only
recently seems to flatten out in some countries.
The underlying tenor beneath the constant flux of newly
published information, articles and case reports suggests
that we have to, at least temporarily, accept a new reality
for our profession and make our clinical care compatible
with the challenges and threats that this pandemic will pose
for the near future. According to projections for transmis-
sion dynamics of COVID-19, recurrent post-pandemic
outbreaks are to be expected until herd immunity is
acquired, which may take until 2024 [27].
The adaptation of surgical and procedural steps for a
risk-minimizing management of potential COVID-19-pos-
itive patients seeking to undergo elective aesthetic proce-
dures in the wake of that wave will present the next big
challenge for the aesthetic surgery community. We propose
a clinical algorithm to enhance patient safety in elective
surgery in the context of COVID-19 and to minimize cross-
contamination between healthcare workers and patients.
Table 3 Model for COVID-19 questionnaire to determine possible risk patients before consultations or procedures (to be performed 24-48 h
before the appointment by phone or e-mail)
Question Yes* No
Are you or any close relative a healthcare provider or work in a hospital?
Where you in contact with COVID-19 patients during the last 30 days?
Were you contaminated or tested positive for COVID 19?
Have you had any episode of fever, cough, sinusitis, anosmia, shortness of breath during the last month?
Have you traveled outside (city of healthcare facility) and surroundings during the last month? (cities or countries)
Were you non-compliant during the lockdown process?
Do you go outside without a face mask/respirator?
Do you wash your hands less than 7 times/day
If any of the questions above is answered with yes, then the patient may be at higher risk of COVID-19 infection and should be classified as high
risk and submitted to screening (refer to Fig. 1)
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New evidence-based guidelines regarding surgical risk
stratification, testing, clinical flow management/contami-
nation management are proposed. We believe that only the
continuous development and broad implementation of
guidelines like the ones proposed in this paper will allow
an early reintegration of all aesthetic procedures into the
scope of surgical care currently performed and to prepare
the elective surgical specialties better for a possible second
wave of the pandemic.
As it is evident from any socioeconomic viewpoint that
we cannot put elective procedures on hold forever, we
believe in the need to define adequate clinical protocols to
carry out elective procedures in this changed epidemiologic
environment. As surgeons performing elective aesthetic
procedures, we feel the obligation to weigh in the risk/
benefit ratio for our clinical decisions even stricter than for
curative procedures, and this article reflects our view on
that commitment toward patient safety.
We hope that the protocols and approaches presented in
this article can be a valuable base for any surgical specialty
looking into redefining new clinical safety guidelines for
elective surgery during the post-pandemic period. As
available evidence data on COVID-19 are evolving
quickly, some of the recommendations in this article may
change as more evidence-based data become available and
testing protocols should be re-evaluated once the relative
infection risk within the population or within one region
becomes clearer. Some of the cited works also identified
weaknesses regarding their experimental study design, and
some referenced manuscripts are preprints and have not
been fully peer-reviewed; therefore, we recommend fol-
lowing up new data available in the future.
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Appendix 1: Recommendations on Organizational
Adaptations for Scheduling, Patient Flow,
Decontamination and Use of PPE in ASCs
and COVID-19-Free Zones in Hospitals
Entrance To minimize contact times and cross-contami-
nation between HCW and patients different entrances
should be used to separate patient and HCW flow. In case
of this not being possible due to structural limitations, we
recommend to space the entrance times for HCW, patients
and deliveries.
Reception/Admission To minimize exposure of seated,
non-moving reception staff signaling for at least 1.5 m
distance keeping while waiting is recommended together
with physical separation (either face shield use or installed
in between the patient area and receptionist) that keep the
load of droplets and airborne smaller.
Visual Information and Signaling :To avoid the need for
assisted guidance to the different areas of the healthcare
facility we suggest creation of color-coding signage for
patient guidance (e.g., colored dots on the floor, colored
lines on the floor or walls and color code in each door or
area entrance).
Consultation and Treatment Room Size Room size should
be adequately big to allow for movement with safety dis-
tance of 1.5–2 m between 1 and 2 HCWs and 1 patient.
Hand Sanitizer There should be a hand sanitizer holder in
each entrance and also in each area of the ASC that permits
sanitizing the hands in between areas.
Shoe Covers/Surgical Mask/Gloves We recommend dis-
pensers (automatic or not) at each entrance.
HCW Changing Room HCW should change into scrubs
and store their street clothes in a bag for clothes tagged
with the name. If there are more than 10 HCW, the user
time flow for changing room use should spaced.
PPE There should be a separated area in changing room
for dispensing specific PPE and also a checklist for PPE.
Adaptation of Agenda
Sufficient spacing between appointments and procedures is
necessary to allow for distancing between patients and
leave time for decontamination.
1. Consultations: We recommend spacing of 30 min in
between consultations to allow patient flow and
cleaning. If more than one doctors are doing consul-
tation on same day than there should be alternated
spacing.
2. Medical/Aesthetic Procedures (e.g., injectables): We
recommend spacing of 40 min
3. Surgeries: We recommend spacing of 90 min
Adaptation of Patient Flow
As many corridors in ASCs or specialty clinics do not
allow to keep distance of min 1.5 m between 2 people
passing, patient flow should be managed by spacing
scheduling to minimize inter patient contact.
Adaptation of Schedule
Reception should perform the pre-questionnaire to decide
the suitability of the patient to come for consultation or
procedure. If all answers are No, the patient qualifies to
come to the clinic (Table 2). The patient should be advised
that they should come alone (exception only for surgeries
that require a companion for post-anesthesia care)
Patient arrival (assuming the pre-questionnaire was
answered with NO)
1. Before entering clinic = hand disinfection with alcohol
gel, put shoe protection and wear mask and gloves. If
possible, patients should bring their own mask
2. Entering and keeping 1.5 m distance from the recep-
tion waiting for instructions
3. Infrared temperature check and asked if hand disin-
fection has been performed.
4. After check-in/admission, receptionist will direct a
color line/CODE to follow
Patient consultation and treatment
1. Consultations
1. Patient will follow color codes to the referred office/
treatment room
2. During consultation 1.5 m distance should be kept,
patient and HCW wear masks, if closer approach
is needed PPE (Fig. 5) should be worn.
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3. HCW and patient disinfect the hands upon entering
the office/treatment room
4. In cases where patients need to be examined naked a
plastic bag should be provided to put clothes
inside during consultation.
5. Patient should repeat disinfection of the hands after
getting dressed.
6. HCW explains the use of every item in the
prescription.
7. Prescriptions and/or medications will be collected in
reception area.
8. Patient should be redirected to reception area; in case
the patient came for multiple purposes such as
pre-op appointment, HCW should advise the
reception that the consultation is over and that
the patient will be redirected to another area.
9. Hands of patient and doctor/aesthetician should be
disinfected upon leaving the office
2. Aesthetic non-surgical procedures
1. Patient will follow color codes to the referred office/
treatment room
2. During consultation/treatment 1.5 m distance should
be kept, patient and HCW wear masks, if closer
approach is needed PPE (Fig. 5) should be worn
3. HCW and patient disinfect the hands upon entering
the office/treatment room
4. Hand disinfection should be done upon entering and
leaving the room
5. Used instruments should be put in a plastic sealable
bag for transport to decontamination area
6. It is not allowed to reuse or any material or to bring
any material from outside clinic
7. In case of body treatments, a plastic drape will be put
under the patient and the therapist needs to wear
a FFP2 mask, gown and gloves (Fig. 5).
8. Prescription and orientations will be printed in
reception and sent by mail or telemedicine apps,
meds and creams will be given to the patients in
a bag with printed prescription inside. Explana-
tions will be given by the HCW in the room
before patient leaves.
9. Patient will follow back the color lines to reception
3. Surgical patient
1. Admission—Patient and max 1 companion will
follow color codes/signing to preoperative area/
ward.
1. Both will disinfect the hands upon arrival and when
leave the room.
2. Room preparation—A kit for each patient should be
left in the bed with a surgical mask and
gloves added. Patient clothes should be put
in a plastic bag while in surgery.
3. After taking off the clothes and putting them in a
plastic bag the patient should pull the hair
with elastic bands and wear a hair cap,
disposable gown and foot protection.
4. Patient marking—if applicable, surgeon should be
alone during marking and wearing PPE
(Fig. 5).
5. Transport to OR–HCW should be wearing PPE,
while transporting the patient to the OR
(Fig. 5)
2. Surgery
1. All HCWs need to disinfect the hands before and
after changing areas between ORs, induction
preparation areas and recovery area.
2. Anesthesia induction should be performed with a
minimum number of HCWs necessary in the
OR when intubation is required and a plastic
drape should be placed over the head and in
chest isolating the intubation area, anes-
thetist should wear double gloves and PPE
[138].
3. Instruments used during anesthesia and surgery
should be sealed in a bag for transporting
them to sterilization room.
4. If surgery is performed on the body, a plastic drape
should be put under the head and another
plastic drape should be placed above the
chest to create a tent isolating the face area.
For sedation procedures, surgical field/drape
may be adapted to cover oral/nasal cavities.
(except for eyelid procedures)
5. After surgery is finished, all the bags should be
closed to transport reusable instruments.
6. All HCWs should stay at least 1.5 m apart while
taking off non reusable PPE and placing it in
protected bins.
7. Hand disinfection should be done after surgery and
after all reusable PPE has been placed in a
plastic box inside OR for decontamination.
8. Not more than one patient should stay in postoper-
ative care area.
9. After determined time, the patient will be transported
by HCW wearing PPE to the room
3. Discharge of patient: At discharge, the patient
should be discharged from its room directly
without necessity to pass by reception. All
instructions and medications/prescriptions should






1. Mail and packages:
Packages should be delivered at the door and not
enter in the clinic.
The packages and mail should be put in a closed
box to be open by the receptionist in a proper time
when the clinic has no patient flow and proper
disinfection can be performed
2. Laboratory and pathology:
1. All samples for laboratory analysis and
pathology will be kept each with the request
inside a sealed bag and all bags inside a closed
box.
2. The collection should be booked for the end
of day and only once a day.
3. Receptionist should place all small bags in a
big sealed bag
4. Receptionist should give the sealed bag to the




1. Prescriptions: The creams/medications
will be handled by the receptionists and
put in a bag along with the prescription
printed for the aesthetic/consultation
patients to take home. For surgical
patients, the bag should be left in the
room before patient leaves.
2. Payments: Payment should be done in
reception preferably with contactless or
with card. If not, money and change
should be passed on by putting it on the
counter, avoid touching of hands when
handling money. (Admins staff needs to
change or disinfect the gloves after han-
dling money.) In surgical cases, the
payment should be ideally done in full
by money transfer before surgery, or upon
arrival in the facility to avoid that the
patient needs to return to reception to pay
after surgery.
3. New appointments should be primarily
given by e-mail/phone/WhatsApp to
avoid patient congestion at reception.
Recommendations on Disinfection
and Decontamination
PPE—Full-face masks, Googles and Face Shields can be
disinfected with ethanol 60–80% and chlorine-containing
disinfectants and this should be done in end of each shift.
Masks—Facial masks and FFP respirators have shown
the potential of for decontamination through either short
steam cycles or dry heat, but more studies are needed to
confirm these recommendations [139, 140].
Instruments—They should be put in a sealed bag for
transport from OR to sterilization room and sterilized fol-
lowing standard facility protocols.
Surfaces—Requirements for surface decontamination
depend on the procedures performed in the area, the
potential grade of contamination during the proce-
dure/consultation and the frequency of use.
We recommend classifying clinical areas in levels of
decontamination:
1. Low level: Regular cleaning with no special
recommendation
2. Moderate level: Reception, waiting room, bathrooms,
patient rooms and consultation rooms should be
cleaned with broad-spectrum enzymatic detergent once
a day and with alcohol (ethanol 60–80%) or similar
surface agent after every patient use.
3. High level: Treatment rooms, ORs and recovery area
or any area where invasive procedures are done, should
be decontaminated using high-to-low surface cleaning
with specific enzymatic detergents providing broad-
spectrum coverage* for bacteria, fungus, spores and
virus (hydro- and lipophilic), e.g., Aniosyme (Anios,
France).
UVC light decontamination is another possible proce-
dure if available at the facility.
*(Approved broad disinfectants according CDC 2020:
chloride solutions, ethanol 60–80%, peracetic acid,
hydrogen peroxide, iodophors or combinations:
ethanol ? quaternary ammonium)
We recommend preparation of the facility before reopening
with Environmental Protection Agency (EPA)-approved
bactericidal and virucidal agent (e.g., Sporicidin) through a
certified disinfecting company. Air conditioners should be
disinfected and cleaned through a certified company. Duct-
based air conditioners that distribute and share air between
different clinical sections should not be used without
adequate decontamination measures (UVC, ionization,
HEPA filters, etc.)




Appendix 2: Proposed Information Form
for Elective Surgery During COVID-19
The healthcare workers of ____________________(Unit/
Department) are strictly following the guidelines and reg-
ulations of local health authorities and international soci-
eties concerning the measures to be taken before, during,
and after the surgical intervention with respect to the
COVID-19 outbreak. Please note that many of these
guidelines are subject to constant change and that we may
adapt them accordingly. Most recent educational material
concerning the hygiene and social distancing measures are
published on the World Health Organization (WHO) Web
site.
Extended hygiene measures are applied to the entire
personnel, facility and equipment used for your treatment.
In particular, disinfection of hands and decontamination of
all relevant surfaces are carried out continuously and
between each single patient contact. Disposable personal
protective equipment (PPE) such as masks, face shields and
gloves is used for our team and patients whenever appli-
cable and appropriate. Any signs of COVID-19 relevant
symptoms in the healthcare team, such as cough or fever,
lead to temporary exclusion from the treatment team and
are subject to further investigation. All of our healthcare
workers get tested periodically. Most of these measures
form a part of standard precautions to reduce transmission
of nosocomial infections and have been in place already
before the COVID-19 outbreak. Novel measures are
therefore complementing and not replacing already estab-
lished clinical practices.
You may be subject to a telephone screening 24 h prior
to the surgery, and during your clinical stay, separation
from other patients in the facility will be pursued whenever
feasible. Furthermore, the body temperatures of patients
patient or any accompanying person will be checked upon
admission.
Preoperative diagnostic testing for COVID-19 may be
performed if you undergo surgical procedures, and you will
be asked to report us any relevant symptoms regarding the
COVID-19 infection. You should notify the healthcare
provider if you are a subject to any increased risks (e.g.,
immunosuppressed patients). As these precautions are also
incorporated in our visiting policies, currently only 1
accompanying person per patient is admitted.
Except in cases of emergency, we are currently only
attending patients with no COVID-19-related symptoms to
reduce the risk of transmission for patients and healthcare
workers.
Please note that there may be amendments in perioper-
ative anesthesia protocols which may also reflect in the
type of anesthesia used and in the preoperative tests being
ordered for your procedures. As always, you will be able to
discuss all options with your anesthetist during the preop-
erative consultation.
To our best knowledge of currently published data, the
risk of COVID-19 infection during your elective treatment
can be considered as low if all the necessary precautions
are taken; however, it cannot be excluded.
Appendix 3: SARS-COV-2 (COVID-19)
Addendum Consent Surgical and Therapeutic
Procedures
There is currently no specific treatment for SARS-CoV-2
coronavirus in patients with suspected or confirmed
COVID-19; however, the information could change rapidly
due to the results or several studies in progress to stop the
virus. In this exceptional circumstance derived from the
COVID-19 pandemic, given the high risk of infectious
transmission of the virus in unavoidable physical proximity
to the patient for medical treatment, it is NOT possible to
endure a NULL RISK of transmission of COVID-19, even
with all the means of protection available, in addition to
those already established. Currently, the biological risk of
COVID-19 is still NOT perfectly known from a scientific
point of view. There is currently no vaccine to prevent
COVID-19, nor is there any specific treatment, so curing
will depend on the signs and symptoms, whether they are
mild, moderate or severe, including pneumonia, acute
respiratory distress syndrome (ARDS), sepsis and septic
shock, as well as the clinical manifestations that occur. The
indications and actions suggested by the corresponding
medical team will be interpreted and applied in an indi-
vidualized manner for each patient, in terms indicated in
the previous paragraph, with the prescriptive freedom of
each health professional remaining for the benefit of the
patient. Particular circumstances of patient conditions with
a high risk of transmission of COVID-19, with serious
consequences for his/her health include people: over 60,
pregnant or immediately postpartum, or diagnosed with
high blood pressure, diabetes mellitus, chronic heart of
lung disease, immunosuppression (acquired or provoked),
or renal or hepatic failure. In this act, the patient
acknowledges that with being the subject of medical
attention, whether by means of a surgical and/or thera-
peutic procedure, there is no guaranteed zero risk of
acquiring the SARS-COV-2 (COVID-19) virus during or
after the act, in the recovery phase. In case of acquisition of
the virus shortly before, during or after treatment, medical
attention or surgical procedure, the clinical evolution may
be different and/or the possibility for the development of
possible perioperative complications including death may
be significantly higher than in COVID-negative patients.
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The patient understands that in spite of numerous and
diligent hygiene and safety measures, medical–surgical
care and outpatient consultations give rise to possibilities
of contagion which he or she understands and expressly
accepts. The patient understands and gives consent to
perioperative test of COVID-19, whether viral charge test
(PCR) or antibody test.
Date
Signature of patient Signature of the healthcare provider
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